Budoprutug for immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new drug called budoprutug for people with immune thrombocytopenia (ITP), a condition where your immune system attacks your own platelets, causing low counts. The study aims to see if the drug can safely raise platelet levels and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your platelet count is very low (below 30,000) even after trying at least one treatment.
- You are not taking certain blood thinners or anti-inflammatory drugs daily.
- You do not have an active infection like hepatitis, HIV, or tuberculosis.
- You have not had certain B-cell treatments (like rituximab) in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called pirtobrutinib for people with immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it can help raise your platelet count and reduce bleeding risk.
This trial compares two treatments for adults recently diagnosed with immune thrombocytopenia (ITP) whose platelet count is very low and hasn't improved with standard steroids. The goal is to find a better way to raise platelet counts and reduce bleeding risk.
This early-phase trial tests an investigational cell therapy called PRG-1801 for people with immune thrombocytopenia (ITP) that hasn't responded to or has come back after standard treatments. It aims to see if PRG-1801 can safely help raise platelet counts.
This trial tests a drug called belantamab mafodotin for adults with primary immune thrombocytopenia (ITP) whose platelet levels stayed low after trying steroids and another treatment like TPO-RA or rituximab. The goal is to see if it safely raises platelet counts.
This trial tests an oral medication called zanubrutinib to find the best dose for adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, leading to low counts and bleeding risk. It may offer a new treatment option for those who haven't had any prior therapy.
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.